PALI-2108, A Colon-Specific PDE4 Inhibitor Prodrug, is Bioactivated in the Colon and Reduces Colon Tissue PDE4B in a Dose-Dependent Manner, Increasing c-AMP and Suppressing TNF-α in A Mouse Model of Colitis

Digestive Disease Week (DDW) 2025
May 3–6, 2025

A Bioinformatic Approach to PALI-2108 Treatment in Ulcerative Colitis Reveals the Potential for Anti-Fibrotic Efficacy with Local PDE4 Inhibition in Intestinal Fibrosis

Digestive Disease Week (DDW) 2025
May 3–6, 2025

PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug, Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model

2025 Crohn’s and Colitis Congress
February 6-8, 2025

Detailing Characteristics of Fibrostenotic Crohn’s Disease Biology & the Potential of a Local PDE4 Inhibitor Prodrug to Minimize Off-Target Effects & Maximize Efficacy

8th Annual Antifibrotic Drug Development (AFDD) Summit
November 21, 2024

Colonic Bioactivation and Potent TNFa Inhibition of PALI-2108 in Human Clinical Studies: A Promising PDE4 Inhibitor Prodrug for the Oral Treatment of Ulcerative Colitis

ACG’s 2024 Annual Scientific Meeting
October 25, 2024

Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment

Digestive Disease Week (DDW) 2024
May 21, 2024

Advancing PALI-2108: Discovery to Strategic Positioning

IBD Innovate: Product Development for Crohn’s & Colitis™
April 9, 2024

Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment

Crohn’s & Colitis Congress 2024
January 26, 2024